News & Updates

Show Multimedia Only
MS patients on certain DMTs may have limited protection from COVID-19 vax

MS patients on certain DMTs may have limited protection from COVID-19 vax

30 May 2022 byRoshini Claire Anthony

The overall rate of hospitalization for COVID-19 is low among patients with multiple sclerosis (MS) treated with disease-modifying therapies (DMTs) who have been vaccinated against COVID-19, according to a prospective study from England. However, patients on ocrelizumab or fingolimod have elevated hospitalization rates.

MS patients on certain DMTs may have limited protection from COVID-19 vax

30 May 2022
Accelerated daratumumab infusion safe, well tolerated in multiple myeloma

Accelerated daratumumab infusion safe, well tolerated in multiple myeloma

29 May 2022